Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of Their COVID 19 Vaccine

Date Time
Share
Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of Their COVID 19 Vaccine
The Pfizer-BioNTech COVID-19 Vaccine is currently available in the U.S. under an Emergency Use Authorization (EUA) granted by the FDA on December 11, 2020. Since then, the companies have delivered more than 170 million doses of the vaccine across the U.S. Submission of a BLA, which requires longer-term follow-up data for acceptance and approval, is the next step in the rigorous FDA review process.
“We are proud of the tremendous progress we’ve made since December in delivering vaccines to millions of Americans, in collaboration with the U.S. Government,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “We look forward to working with the FDA to complete this rolling submission and support their review, with the goal of securing full regulatory approval of the vaccine in the coming months.”

Related Keywords

United States ,Canada ,United Kingdom ,Americans ,Albert Bourla ,Ugur Sahin ,Centers For Disease ,Pfizer ,European Union ,Drug Administration ,Vaccine Administration Under Emergency Use Authorization ,Emergency Use Authorization ,Chief Executive Officer ,Marketing Authorization Holder ,Coronavirus Disease ,Fact Sheet ,Healthcare Providers Administering Vaccine ,Vaccination Providers ,Disease Control ,Adverse Events ,Mandatory Requirements ,Administration Under Emergency Use ,ஒன்றுபட்டது மாநிலங்களில் ,கனடா ,ஒன்றுபட்டது கிஂக்டம் ,அமெரிக்கர்கள் ,மையங்கள் க்கு நோய் ,ஃபைசர் ,ஐரோப்பிய தொழிற்சங்கம் ,அவசரம் பயன்பாடு அங்கீகாரம் ,தலைமை நிர்வாகி அதிகாரி ,சந்தைப்படுத்தல் அங்கீகாரம் வைத்திருப்பவர் ,உண்மை தாள் ,தடுப்பூசி வழங்குநர்கள் ,நோய் கட்டுப்பாடு ,கட்டாயமாகும் தேவைகள் ,